Medical long body and medical long body set

Abstract

[Problem] To provide a medical long body capable of lessening a physical load on the patient by reducing the time required for hemostasis of the wound site through administration of a pharmaceutical agent such as a hemostatic agent to a wound site such as a punctured site by a simple manipulation. [Solution] The sheath 100 for an introducer according to the present invention comprises: a catheter body 110; a hub body 120 fixed to a base end part of the catheter body; and a support member 130 that is linked to the hub body and is configured to cover the base end part of the catheter body. The catheter body has a recessed part 112 on an outer surface thereof. The support member is disposed so as to partially cover the recessed part. The support member has a pharmaceutical agent part 131 containing a pharmaceutical agent, and a partition wall part 132 located between the pharmaceutical agent part and the recessed part. The partition wall part is configured to connect the pharmaceutical agent part with the recessed part when the partition wall part is destroyed by pressure or damage.

Description

[Technical field]

[0001] The present invention relates to a medical elongate body and a medical elongate body set used in an introducer assembly, which is a medical instrument. [Background technology]

[0002] In the medical field, procedures are performed to percutaneously introduce various catheters into a living body. In such procedures, in order to percutaneously insert various catheters into a living body, an introducer sheath is used as a medical instrument that connects the inside of the living body with the outside of the living body. For example, the introducer sheath includes a catheter body that is percutaneously inserted into a living body lumen such as a blood vessel, and a hub body that is connected to the base end side of the catheter body.

[0003] In a procedure using an introducer sheath, the surgeon, with a dilator inserted into the introducer sheath, inserts the catheter body of the introducer sheath percutaneously into a blood vessel through a puncture site (perforation) formed in a patient's limb or the like. With the catheter body inserted into the blood vessel, the surgeon removes the dilator from the introducer sheath. As a result, the introducer sheath forms an access path connecting the inside of the body and the outside of the body with the catheter body percutaneously inserted into the body lumen. After removing the dilator from the introducer sheath, the surgeon can insert a guidewire or various catheters into the blood vessel through the lumen of the catheter body.

[0004] The surgeon inserts a guidewire or various catheters into a blood vessel, treats a lesion within the blood vessel, and then removes the introducer sheath from the blood vessel and performs hemostasis at the puncture site where the introducer sheath was inserted. Typically, when performing hemostasis at the puncture site, the surgeon applies pressure to the puncture site using a hemostatic device or the like that applies pressure to the puncture site.

[0005] However, to stop bleeding at the puncture site, it is necessary to apply pressure to the puncture site for a long period of time. In addition, the surgeon must operate the hemostatic device so that the pressure applied to the puncture site by the hemostatic device decreases over time to prevent artery blockage even during long-term hemostatic procedures. Therefore, there is a demand for a technology that can stop bleeding in a short period of time in order to reduce the physical burden on the patient involved in stopping bleeding at the puncture site and simplify the surgeon's hemostatic procedures.

[0006] In recent years, as described in Patent Document 1, a method has been proposed to promote hemostasis at the puncture site by placing a hemostatic agent that enables wound healing on the outer surface of the catheter body of the introducer sheath in order to shorten the time required to stop bleeding at the puncture site and reduce the physical burden on the patient. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] International Publication No. 2018 / 043427 Summary of the Invention [Problem to be solved by the invention]

[0008] The introducer sheath described in Patent Document 1 has a hemostatic agent disposed on the outer surface of the catheter body. In addition, the introducer sheath described in Patent Document 1 covers the hemostatic agent with a cover member or strain relief to prevent the hemostatic agent from peeling off from the catheter body before being introduced into the puncture site and to prevent the hemostatic agent from coming into contact with the fingers of the surgeon or surrounding objects and being lost due to abrasion or the like.

[0009] However, when the introducer sheath of Patent Document 1 introduces a hemostatic agent to a puncture site, it is necessary to remove the cover member or strain relief covering the hemostatic agent and expose the hemostatic agent on the surface of the catheter body. In addition, after exposing the hemostatic agent on the surface of the catheter body, the introducer sheath of Patent Document 1 needs to push the catheter body further into the blood vessel so that the hemostatic agent is placed at the puncture site. Therefore, when using the introducer sheath of Patent Document 1 to place a hemostatic agent at a puncture site, the surgeon needs to remove the cover member or strain relief so as not to come into contact with the hemostatic agent, and then carefully move the catheter body so as not to come into contact with the hemostatic agent. Therefore, in consideration of the operability of the surgeon, the introducer sheath disclosed in Patent Document 1 has room for improvement in terms of the structure when administering a hemostatic agent to a puncture site.

[0010] At least one embodiment of the present invention has been made to solve the above-mentioned problems, and aims to provide a medical elongated body that can administer a hemostatic agent or other drug to a wound site, such as a puncture site, through a simple operation, thereby shortening the time required to stop bleeding at the wound site and reducing the physical burden on the patient. [Means for solving the problem]

[0011] A medical elongated body according to one embodiment of the present invention includes a catheter body, a hub body fixed to a base end of the catheter body, and a support member connected to the hub body and configured to cover a part of the base end side of the catheter body. The catheter body has a recess on an outer surface of the catheter body, and the support member is arranged to partially cover the recess. The support member has a drug portion containing a medicinal solution and a partition portion located between the drug portion and the recess, and the partition portion is configured to communicate between the drug portion and the recess when it is destroyed by pressure or damage. The medical elongate body has a needle member having a sharp tip portion configured to be capable of destroying the partition portion, and a space portion between the catheter body and the support member, adjacent to the drug portion across the partition portion. The tip portion of the needle member is configured to be positioned in the space portion. Moreover, one embodiment of the present invention is medicineThe medical elongate body set includes a medical elongate body and a needle member having a sharp tip portion configured to be able to destroy a partition portion. In the medical elongate body set, the support member of the medical elongate body includes a marker portion that serves as a guide when inserting the needle member in the circumferential direction of the catheter main body. Effect of the Invention

[0012] According to the medical elongated body and medical elongated body set of the embodiment of the present invention, a medicinal liquid can be administered to a wound site through the recess of the catheter body by a simple operation, shortening the time required for hemostasis at the wound site of the patient and reducing the burden on the patient and the surgeon. That is, the medical elongated body is inserted into a blood vessel from a puncture site percutaneously, and in a state in which the recess of the catheter body is inserted into the wound site (puncture site), the partition of the support member is destroyed by a simple operation such as pressing the support member, and the medicinal liquid held by the medicinal part of the support member can be administered to the wound site through the recess of the catheter body. In addition, since the operation of the surgeon to administer the medicinal liquid to the wound site using the medical elongated body is only the operation of destroying the partition, the medicinal liquid can be administered to the wound site without moving the catheter body placed at the wound site. In addition, since the medical elongated body is arranged so that the support member partially covers the recess, the surgeon can be prevented from coming into contact with the medicinal liquid when administering the medicinal liquid to the wound site. Therefore, the surgeon can administer the medicinal liquid to the wound site with a simple operation, and the hemostatic effect of the medicinal liquid can shorten the time required for hemostasis at the wound site. In particular, when used in combination with a hemostatic device that compresses and stops the hemostasis at a wound site such as a puncture site, the medicinal liquid can shorten the time required for hemostasis, thereby reducing the surgeon's efforts in decompression and other operations and reducing the risk of arterial occlusion. Furthermore, since the medical elongated body has a partition between the drug portion and the recess, it is possible to prevent the medicinal liquid from being administered to the wound site before the partition is destroyed after the catheter main body is percutaneously inserted into a blood vessel from the wound site. Therefore, the surgeon can destroy the partition of the support member by pressure or damage at any time and administer the medicinal liquid to the wound site. [Brief description of the drawings]

[0013] [Figure 1] FIG. 2 is a diagram showing a medical elongated body according to the first embodiment. [Diagram 2] 1 is a cross-sectional view of a medical elongate body according to a first embodiment. [Diagram 3] 3 is an enlarged view of the dashed line portion 3 in FIG. 2. FIG. [Figure 4] 4A and 4B are schematic cross-sectional views for explaining a method of placing a medical elongated body in accordance with the first embodiment, in which FIG. 4(A) is a view showing the state of inserting an introducer needle, FIG. 4(B) is a view showing the state of inserting a guidewire into a biological lumen, FIG. 4(C) is a view showing the state of the guidewire placed in the biological lumen, FIG. 4(D) and FIG. 4(E) are views showing the state of puncturing an introducer assembly, and FIG. 4(F) is a view showing the state of the medical elongated body placed in a biological lumen. [Diagram 5] FIG. 2 is a view showing a state in which a medical elongated object is placed in a biological lumen. [Figure 6] FIG. 6(A) is a schematic cross-sectional view showing how the medicinal liquid of the medicinal portion is introduced into a wound site, and FIG. 6(B) is an enlarged view showing the vicinity of the wound site in FIG. 6(A). [Figure 7] 7(A) and 7(B) are views showing modified examples of the support member and needle member, which correspond to the left side of the center line in FIG. [Figure 8] 13 is a view showing a medical elongated body set relating to a modified example of the support member and the needle member, illustrating a portion corresponding to the left side of the center line in FIG. [Figure 9] 13 is a view showing a medical elongated body set according to a modified example of the support member and needle member, the portion corresponding to the left side of the center line in FIG. 3. FIG. [Figure 10] FIG. 10(A) shows a modified support member and needle member corresponding to the portion to the left of the center line in FIG. 3, and FIG. 10(B) shows a transparent portion of the support member in FIG. 10(A) and also shows the drug portion, needle member, etc. as viewed from the radially outward direction of the catheter body. [Figure 11] 5 is a diagram showing a portion of a medical elongate body according to a second embodiment, the portion corresponding to the left side of the center line in FIG. [Figure 12]FIG. 11 is a perspective view of a medical elongate body according to a modified example of the second embodiment, showing a support member, a needle member, a cover member, etc.; [Figure 13] 13 is a cross-sectional view perpendicular to the longitudinal direction of the catheter body, showing a support member, a needle member, a cover member, a recess, etc. in the medical elongate body of FIG. 12. FIG. [Figure 14] 11 is a diagram showing a modified example of a recess of a catheter body corresponding to the modified example of FIG. 10. FIG. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] Hereinafter, the embodiments for carrying out the present invention will be described in detail with reference to the drawings. The embodiments shown here are merely illustrative in order to embody the technical idea of ​​the present invention, and do not limit the present invention. Furthermore, all other possible embodiments, examples, and operating techniques that can be conceived by those skilled in the art without departing from the gist of the present invention are included in the scope and gist of the present invention, and are included in the scope of the inventions described in the claims and their equivalents.

[0015] Furthermore, for the convenience of illustration and ease of understanding, the drawings attached to this specification may be represented diagrammatically with appropriate changes in scale, aspect ratio, shape, etc. from the actual product; however, these are merely examples and are not intended to limit the interpretation of the present invention.

[0016] In the following description, ordinal numbers such as "first" and "second" are used, but unless otherwise specified, these are used for convenience and do not dictate any order.

[0017] The medical elongated body according to one embodiment of the present invention is applied to introducer sheaths 100, 100a, 100b, 100c, 100d, 100e, 100f, and 100g constituting the introducer assembly 10, but the application is not particularly limited. In addition, the contents of specific procedures and treatment procedures using the medical elongated body according to one embodiment of the present invention are also representative examples and do not specify the present invention.

[0018] (First embodiment) Hereinafter, a medical elongated body according to the first embodiment will be described with reference to the drawings. In the first embodiment, the medical elongated body is an example applied to a sheath for introducer 100 constituting an introducer assembly 10.

[0019] 1 to 3 are diagrams for explaining each part of the introducer assembly 10, and FIGS. 4 to 6 are diagrams for explaining a treatment method using the introducer sheath 100. As shown in FIG.

[0020] With reference to Fig. 2, in this specification, the side of the introducer sheath 100 where the hub body 120 is disposed (upper side in Fig. 2) is referred to as the "base end side". The side of the introducer sheath 100 that is positioned opposite the base end side and that is introduced into the biological lumen R (lower side in Fig. 2) is referred to as the "distal side". The direction in which the introducer sheath 100 extends (up and down direction in Fig. 2) is referred to as the "axial or longitudinal direction". Furthermore, the "distal portion" refers to a certain range including the tip (the most distal end) and its periphery, and the "base end" refers to a certain range including the base end (the most proximal end) and its periphery.

[0021] Also, with reference to Figures 6(A) and 6(B), a portion of the biological tissue W, such as a puncture site, that is wounded when the introducer sheath 100 is percutaneously introduced into the biological lumen R is referred to as a "wound site P."

[0022] As shown in Fig. 1, the introducer assembly 10 according to this embodiment includes an introducer sheath 100 and a dilator 200. The introducer sheath 100 and the dilator 200 will be described in detail below.

[0023] <Introducer sheath> The introducer sheath 100 is placed in a biological lumen R such as a blood vessel, and is used to insert a treatment instrument such as a catheter or a guide wire into the lumen 116 and introduce them into the biological lumen R. A procedure such as percutaneous transluminal coronary angioplasty (PTCA / PCI) can be performed using the guide wire introduced into the biological lumen R. Approaches for percutaneous transluminal coronary angioplasty include TFI (Trans Femoral Intervention), in which an introducer sheath corresponding to a medical long body is introduced from an artery at the base of the leg (femoral artery), and TRI (Trans Radial Intervention), in which an introducer sheath is introduced from an artery at the wrist (radial artery).

[0024] As shown in Fig. 2 and Fig. 4(F), the introducer sheath 100 includes a catheter body 110 configured to be percutaneously introduced into a biological lumen R, and a hub body 120 connected to the base end side of the catheter body 110. The introducer sheath 100 includes a support member 130 connected to the hub body 120 and configured to cover a part of the base end side of the catheter body 110, and a cover member 160 configured to be positioned from a position on the base end side of the tip of the support member 130 to a position on the tip end side of the support member 130. The support member 130 includes a medicinal section 131 and a partition section 132. Details will be described later.

[0025] (Catheter body) The catheter body 110 is composed of a substantially cylindrical tubular member having an extending lumen 116. As shown in Fig. 2, the catheter body 110 has a tapered tip portion 111, a main body portion 115 located on the proximal side of the tip portion 111, and a proximal end portion 113 located on the proximal side of the main body portion 115 and connected to a hub body 120.

[0026] The catheter main body 110 also has a recess 112 on the outer surface of the catheter main body 110. The recess 112 is provided from a position on the base end side of the main body section 115 of the catheter main body 110 to a position on the tip side of the tip of the support member 130. In addition, at least a part of the recess 112 on the base end side in the longitudinal direction of the catheter main body 110 is covered by the support member 130. In this embodiment, the recess 112 on the base end side in the longitudinal direction of the catheter main body 110 is partially covered by the support member 130 and the cover member 160. This allows the drug solution in the drug section 131 to flow out from the base end side of the recess 112 toward the tip side of the recess 112 when the partition section 132 is destroyed as described below.

[0027] The recess 112 is provided in a part of the outer surface of the catheter body 110 in the circumferential direction of the catheter body 110. The shape of the tip of the recess 112 is not particularly limited as long as it allows the medicinal liquid of the medicinal section 131 to flow out to the wound site P when the recess 112 of the catheter body 110 is inserted into the wound site P. For example, the tip of the recess may be configured so that the depth of the recess gradually decreases from the base end side of the recess toward the tip side of the recess. The recess 112 is configured to be provided at one location in the circumferential direction of the catheter body 110.

[0028] The depth of the recess 112 can be set, for example, in the range of 0.01 mm to 0.15 mm, and the width of the recess 112 (the length in the longitudinal direction of the catheter main body 110) can be set, for example, in the range of 10 mm to 30 mm.

[0029] The recess 112 is configured to face a space 180 of the support member 130, which will be described later. That is, the space formed by the recess 112 is connected to the space 180 of the support member 130. As a result, when the surgeon destroys the partition 132, the medicinal liquid of the medicinal portion 131 flows into the recess 112 through the space 180 and flows out from the tip side of the recess 112 to the wound site P, so that the surgeon can administer the medicinal liquid to the wound site P.

[0030] The material of the catheter body 110 is not particularly limited, but examples of the material that can be used include polymeric materials such as polyolefin (e.g., polyethylene, polypropylene, polybutene, ethylene-propylene copolymer, ethylene-vinyl acetate copolymer, ionomer, or a mixture of two or more of these), polyolefin elastomer, crosslinked polyolefin, polyvinyl chloride, polyamide, polyamide elastomer, polyester, polyester elastomer, polyurethane, polyurethane elastomer, fluororesin, polycarbonate, polystyrene, polyacetal, polyimide, polyetherimide, polyetheretherketone, and mixtures of these.

[0031] (Hub body) The hub body 120 is fixed to the proximal end of the catheter body 110. As shown in Fig. 2, the hub body 120 has an inner lumen 122 to which the proximal end 113 of the catheter body 110 is fixed, and a side port 124 communicating with the inner lumen 122.

[0032] One end of a flexible tube 151 (see FIG. 1) is liquid-tightly connected to the side port 124. For example, a three-way stopcock 150 is attached to the other end of the tube 151. It is possible to inject a liquid such as physiological saline from the port of this three-way stopcock 150 through the tube 151 into the lumen 116 of the catheter body 110. The tube 151 can be made of a known tube made of, for example, polyvinyl chloride.

[0033] Although there are no particular limitations on the material that can be used to form the hub body 120, a hard material such as a hard resin is preferable. Specific examples of hard resins include polyolefins such as polyethylene and polypropylene, polyamides, polycarbonates, and polystyrene.

[0034] A hemostatic valve 140 is attached to the base end 123 of the hub body 120 to prevent blood that has flowed into the catheter body 110 from leaking to the outside. The hemostatic valve 140 is made of an elastic member with a cross cut 140a that allows the dilator body 210 to be inserted. The hemostatic valve 140 is formed in a substantially elliptical membrane (disc shape), and is fixed to the hub body 120 in a liquid-tight manner by fitting a specified cap 145 into it.

[0035] The constituent material of the hemostasis valve 140 is not particularly limited, but examples thereof include elastic materials such as silicone rubber, latex rubber, butyl rubber, and isoprene rubber.

[0036] The base end 113 of the catheter body 110 is fixed to the connecting portion 125a of the hub body 120. The base end 113 of the catheter body 110 and the connecting portion 125a of the hub body 120 can be fixed by, for example, an adhesive.

[0037] (Support member) The support member 130 is connected to the hub body 120 and is configured to cover a portion of the base end side of the catheter body 110. As shown in Fig. 2, the support member 130 is fitted over the catheter body 110 and the hub body 120. The support member 130 covers the tip portion 121 of the hub body 120 and surrounds a predetermined range on the base end side of the catheter body 110. The support member may be fixed to the hub body with an adhesive or the like, or may be detachably connected to the hub member by fitting or the like.

[0038] By covering the area between the catheter body 110 and the hub body 120, the support member 130 prevents the catheter body 110 from kinking between the catheter body 110 and the hub body 120 during operations such as inserting the introducer sheath 100 into a biological lumen.

[0039] The constituent material of the support member 130 (other than the partition wall portion 132) is not particularly limited, and examples thereof include natural rubber, silicone resin, and the like. The constituent material of the partition wall portion 132 of the support member 130 may be natural rubber, silicone resin, and the like, similar to the constituent material of the support member 130 (other than the partition wall portion 132), or a resin material such as polyvinylidene chloride or polyvinyl chloride may be used. Note that, from the viewpoint of fusion to the support member 130 (other than the partition wall portion 132) or ease of installation on the support member 130 (other than the partition wall portion 132), the partition wall portion 132 of the support member 130 is preferably made of the same material as the constituent material of the support member 130 (other than the partition wall portion 132).

[0040] As shown in FIG. 2 and other figures, support member 130 has drug section 131 containing a drug solution, and partition section 132 located between drug section 131 and recess 112.

[0041] The medicinal agent portion 131 is composed of a solution containing a known material having a hemostatic effect, such as a metal ion that accelerates the repair of the wound site P, or a hemostatic agent such as tranexamin or carbazochrome sodium sulfonate.

[0042] 2 and 3, drug section 131 is disposed in the internal space of support member 130. Drug section 131 is held in the internal space of support member 130 by partition section 132.

[0043] Since the medicinal agent portion 131 is held in the internal space of the support member 130, it does not come into contact with the biological tissue W when the introducer sheath 100 is percutaneously inserted into the biological lumen R. Therefore, the medicinal agent portion 131 is not reduced by abrasion or the like when the introducer sheath 100 is inserted into the biological lumen R, and is not administered to the biological tissue W at a timing not intended by the surgeon. In addition, the medicinal agent portion 131 can release a part of the medicinal solution by destroying the partition wall portion 132 with the needle member 170, and the medicinal solution can flow out to the biological tissue W through the recess 112 and come into contact with the biological tissue W. Therefore, after introducing a diagnostic device or a treatment device through the introducer sheath 100 and diagnosing or treating a lesion in the biological lumen R, the surgeon can administer the medicinal solution to the wound site P at any timing before removing the introducer sheath 100 from the biological lumen R, and the hemostatic effect of the medicinal solution can shorten the hemostatic time at the wound site P.

[0044] 3, the partition 132 of the support member 130 is configured to communicate between the medicinal section 131 and the recess 112 when it is broken due to damage. Specifically, the partition 132 forms a part of the inner surface of the support member 130 that covers the outer surface of the catheter body 110, and prevents the medicinal solution in the medicinal section 131 from being discharged to the outside of the support member 130.

[0045] As a result, the support member 130 can release the medicinal liquid in the medicinal portion 131 by breaking the partition portion 132, and the medicinal liquid can flow out into the recess 112 of the catheter main body 110. Therefore, the surgeon can release the medicinal liquid in the medicinal portion 131 contained in the internal space of the support member 130 into the recess 112 by breaking the partition portion 132, and administer the medicinal liquid in the medicinal portion 131 to the wound site P in a state in which the introducer sheath 100 is placed in the biological lumen R.

[0046] The space 180 is formed between the catheter body 110 and the support member 130 when the support member 130 is attached to the catheter body 110 (when the support member 130 is fitted onto the catheter body 110 and the hub body 120). Specifically, the space 180 is formed between the outer surface of the catheter body 110 and the inner surface of the support member 130 at a position connected to the space formed by the recess 112 of the catheter body 110. The space 180 is configured to be adjacent to the drug section 131 with the partition section 132 sandwiched between the catheter body 110 and the support member 130. In this embodiment, as shown in FIG. 3, the space 180 is configured to be located on the proximal side with respect to the drug section 131 and the partition section 132.

[0047] The partition 132 is broken by the needle member 170. The needle member 170 has a sharp tip 171 capable of breaking the partition 132, a main body 172 located on the base end side of the tip 171, and a base 173 located outside the support member 130. In this embodiment, as shown in FIG. 3, the tip 171 of the needle member 170 is inserted into the support member 130 so as to face the tip side of the catheter body 110. The tip 171 of the needle member 170 is located in the space 180, and a part of the main body 172 is located outside the support member 130. The base 173 is located at a position different from the drug section 131 in the longitudinal direction of the catheter body 110.

[0048] 2, the shape of the support member 130 includes a tip region Y1, an intermediate region Y2 connected to the tip region Y1, disposed closer to the base end of the catheter main body 110 than the tip region Y1, and extending while inclining in a direction away from the outer surface of the catheter main body 110, and a base region Y3 connected to the intermediate region Y2 and disposed closer to the base end than the intermediate region Y2. In this embodiment, as shown in FIG. 2, in order to ensure space for the drug section 131 and the space section 180, the drug section 131 and the partition section 132 are disposed in the base region Y3 of the support member 130. The base region Y3 of the support member 130 is a region connected to the hub body 120, and has an outer diameter larger than the tip region Y1 and the intermediate region Y2.

[0049] However, the shape of support member 130 is not limited to this as long as it can form the above-mentioned drug section 131, partition section 132, and space section 180. In addition, in this embodiment, drug section 131 is provided on a part of support member 130, not on the entire circumference in the circumferential direction (angular direction), but may be provided on the entire circumference in the internal space of the support member.

[0050] (Cover material) The cover member 160 is configured to be located from a position on the proximal side of the tip of the support member 130 to a position on the distal side of the tip of the support member 130 in the longitudinal direction of the catheter main body 110. In this embodiment, as shown in FIG. 3, the cover member 160 is fixed to the support member 130 and configured to cover a part of the recess 112. In this embodiment, the cover member 160 is fixed to the support member 130 with a certain gap between the proximal end of the cover member 160 and the hub main body 120. Therefore, the proximal end of the recess 112 is located between the proximal end of the cover member 160 and the hub main body 120 in the longitudinal direction of the catheter main body 110 so as to face the space portion 180. In addition, the tip of the cover member 160 is arranged to be located on the proximal side of the position of the tip of the recess 112.

[0051] The cover member 160 is disposed in the biological tissue W such that the tip of the recess 112 of the catheter main body 110 is located at the wound site P when the catheter main body 110 is inserted into the biological tissue W. For this reason, the cover member 160 is preferably configured so that the outer diameter of the cover member 160 is larger than the outer diameter of the catheter main body 110 so as to obtain the effect of preventing the catheter main body 110 from coming off from the biological tissue W. In addition, the cover member 160 is preferably configured from a metal material or a fluorine-based resin that is harder than the material of the catheter main body 110 so that the outer diameter of the cover member 160 can be maintained when the catheter main body 110 is inserted into the biological tissue W and the cover member 160 can be smoothly inserted into the biological tissue W. Note that, in order to obtain the effect of preventing the catheter main body 110 from coming off, the surface of the cover member 160 may be partially or entirely subjected to a treatment (such as blasting) to increase the surface roughness.

[0052] (Dilator) As shown in FIG. 1, the dilator 200 has a dilator body 210 formed of a tubular body that can be inserted into the catheter body 110, and a dilator hub 220 that can be connected to the hub body 120.

[0053] The dilator 200 is used to prevent the catheter body 110 from bending and to widen a perforation in the skin when the catheter body 110 of the introducer sheath 100 is inserted into the biological lumen R.

[0054] When the dilator body 210 is inserted into the catheter body 110, its tip portion 211 protrudes from the tip portion 111 of the catheter body 110. The tip portion 211 of the dilator body 210 is formed in a tapered shape tapering toward the tip side.

[0055] The material constituting the dilator body 210 is not particularly limited, and it is possible to use the same material as that conventionally used for the dilator body 210. Specific examples include polyolefins such as polypropylene (PP) and polyethylene (PE), polyesters such as nylon and polyethylene terephthalate (PET), and fluorine-based polymers such as polyvinylidene fluoride (PVDF) and tetrafluoroethylene-hexafluoropropylene copolymer (FEP).

[0056] Although there is no particular limitation on the material that constitutes the dilator hub 220, a hard material such as a hard resin is preferable. Specific examples of hard resins include polyolefins such as polyethylene and polypropylene, polyamides, polycarbonates, and polystyrene.

[0057] Next, an example of use of the sheath for introducer 100 will be described with reference to Figs. 4(A) to 4(F), 5, and 6(A) to 6(B).

[0058] In Figures 4(A) to 4(F), an introducer sheath 100 is percutaneously inserted into a biological lumen R through a wound site P, such as a puncture site, formed in a patient's limb, and a catheter body 110 of the introducer sheath 100 is placed in the biological lumen R. Specifically, in Figures 4(A) to 4(F), the introducer needle 50 is inserted into the biological lumen R where the introducer sheath 100 is to be placed (see Figure 4(A)), the guidewire 60 is inserted into the biological lumen R through the inner lumen 50a of the introducer needle 50 (see Figure 4(B)), the introducer needle 50 is removed from the biological lumen R while leaving the guidewire 60 in the biological lumen R, and the guidewire 60 is left in the biological lumen R (see Figure 4(C)), the introducer assembly 10 is punctured while the dilator 200 is aligned with the guidewire 60 placed in the biological lumen R (see Figures 4(D) and 4(E)), and the guidewire 60 and the dilator 200 are removed from the introducer sheath 100 while leaving the introducer sheath 100 in the biological lumen R (see Figure 4(F)). When the catheter body 110 is placed in the body lumen R, the introducer sheath 100 is positioned so that the tip of the recess 112 of the catheter body 110 is positioned within the body tissue via the wound site P.

[0059] After placing the introducer sheath 100 in the biological lumen R, the surgeon introduces a treatment instrument such as a catheter or a guidewire into the biological lumen R through the hemostatic valve 140 of the introducer sheath 100, and performs treatment of the diseased area in the biological lumen R (e.g., a procedure such as percutaneous coronary angioplasty).

[0060] After the predetermined procedure is completed, as shown in Figs. 5 and 6(A), the operator, with the tip of the recess 112 of the catheter main body 110 positioned in the living tissue, pushes in the base 173 of the needle member 170 positioned outside the support member 130, moves the tip 171 of the needle member 170 from the space 180 toward the partition 132, and damages and destroys the partition 132. As a result, the medicinal liquid of the medicinal portion 131 is released toward the tip side of the recess 112 through the space 180 and the recess 112. Then, the medicinal liquid of the medicinal portion 131 is administered to the wound site P through the tip of the recess 112. Note that the recess 112 and the space 180 of the introducer sheath 100 may be filled with blood or the like during the predetermined procedure. In this case, when base 173 of needle member 170 located outside support member 130 is pressed in and partition 132 is destroyed, the medicinal liquid in medicinal portion 131 is dissolved in blood or the like and administered to wound site P via the tip of recess 112. The timing for the surgeon to press in base 173 of needle member 170 and destroy partition 132 may be before a predetermined procedure is completed. For example, the surgeon may consider the penetration time of the medicinal liquid in medicinal portion 131 into the biological tissue, and may press in base 173 of needle member 170 and destroy partition 132 during the predetermined procedure to administer the medicinal liquid into the biological tissue.

[0061] 6(B), the medicinal liquid of the medicinal section 131 administered to the wound site P is absorbed by the wound site P and the living tissue surrounding the wound site P, thereby treating the wound and stopping the bleeding. After the prescribed procedure is completed and the medicinal liquid of the medicinal section 131 is administered to the wound site P, the introducer sheath 100 is removed from the living lumen R. At this time, in order to shorten the time required for the medicinal liquid to stop the bleeding, pressure hemostasis may be performed with a hemostatic device or the like when the introducer sheath 100 is removed from the living lumen R, if necessary.

[0062] As described above, the introducer sheath 100 according to this embodiment includes the catheter body 110, the hub body 120 fixed to the base end of the catheter body 110, and the support member 130 connected to the hub body 120 and configured to cover a part of the base end side of the catheter body 110. The catheter body 110 has a recess 112 on the outer surface of the catheter body 110. The support member 130 is disposed so as to partially cover the recess 112. The support member 130 has a drug section 131 containing a drug solution, and a partition section 132 located between the drug section 131 and the recess 112. The partition section 132 is configured to communicate between the drug section 131 and the recess 112 when it is destroyed by damage.

[0063] With this configuration, the medicinal liquid can be administered to the wound site P through the recess 112 of the catheter main body 110 by a simple operation, shortening the time required for hemostasis at the wound site P of the patient and reducing the burden on the patient and the surgeon. That is, the introducer sheath 100 is configured such that the catheter main body 110 is percutaneously inserted into a blood vessel from the wound site P, and in a state in which the recess 112 of the catheter main body 110 is inserted into the wound site P, the partition wall 132 of the support member 130 is destroyed by a simple operation such as pressing the support member 130, thereby allowing the medicinal liquid held in the medicinal portion 131 of the support member 130 to be administered to the wound site P through the recess 112 of the catheter main body 110. Furthermore, the operation of the surgeon administering the medicinal liquid to the wound site P using the introducer sheath 100 is only the operation of destroying the partition wall 132, so that the medicinal liquid can be administered to the wound site P without moving the catheter main body 110 placed in the wound site P. In addition, since the introducer sheath 100 is arranged so that the support member 130 partially covers the recess 112, when the operator administers the medicinal liquid to the wound site P, the operator can be prevented from coming into contact with the medicinal liquid. Therefore, the operator can administer the medicinal liquid to the wound site P with a simple operation, and the hemostatic effect of the medicinal liquid can shorten the time required for hemostasis at the wound site P. In particular, when the introducer sheath 100 is used in combination with a hemostatic device that compresses the wound site P to stop bleeding, such as a puncture site, the hemostatic time can be shortened by the medicinal liquid, reducing the operator's effort in decompressing the wound site P and reducing the risk of arterial occlusion. Furthermore, since the introducer sheath 100 has a partition wall 132 between the medicinal portion 131 and the recess 112, the medicinal liquid can be prevented from being administered to the wound site P before the partition wall 132 is destroyed after the catheter main body 110 is percutaneously inserted into the blood vessel from the wound site P. Therefore, the surgeon can destroy the partition portion 132 of the support member 130 by applying pressure or damaging it, and administer the medicinal liquid to the wound site P at any time.

[0064] The introducer sheath 100 also has a needle member 170 having a tip portion 171 configured to be capable of destroying the partition portion 132, and a space portion 180 adjacent to the medicinal agent portion 131 across the partition portion 132 between the catheter main body 110 and the support member 130. The tip portion 171 of the needle member 170 is configured to be located in the space portion 180. In this manner, the tip portion 171 of the needle member 170 is located in the space portion 180 adjacent to the medicinal agent portion 131 across the partition portion 132. Therefore, the surgeon can easily destroy the partition portion 132 and release the medicinal solution in the medicinal agent portion 131 by moving the tip portion 171 of the needle member 170 from the space portion 180 to the partition portion 132. Therefore, with the recess 112 of the catheter body 110 inserted into the wound site P, the surgeon can administer the medicinal liquid contained in the medicinal section 131 of the support member 130 to the wound site P via the recess 112 of the catheter body 110.

[0065] The needle member 170 has a tip portion 171 and a main body portion 172 located on the base end side of the tip portion 171, and is configured such that a part of the main body portion 172 of the needle member 170 is located outside the support member 130. In this manner, the needle member 170 is configured such that a part of the main body portion 172 of the needle member 170 is located outside the support member 130. Therefore, the surgeon can operate the tip portion 171 of the needle member 170 and destroy the partition portion 132 by operating the part of the main body portion 172 of the needle member 170 located outside the support member 130. Therefore, the surgeon can operate the needle member 170 located outside the support member 130 with the recess 112 of the catheter main body 110 inserted into the wound site P, and can more easily administer the medicinal liquid held by the medicinal portion 131 of the support member 130 to the wound site P via the recess 112 of the catheter main body 110.

[0066] Moreover, the needle member 170 has a base portion 173 located outside the support member 130, and the base portion 173 is configured to be located at a position different from the medicinal portion 131 in the longitudinal direction of the catheter main body 110. Therefore, the needle member 170 is positioned so that the tip portion 171 of the needle member 170 faces the direction of the medicinal portion 131, and is disposed obliquely so that the base portion 173 of the needle member 170 is located at a position different from the medicinal portion 131 in the longitudinal direction of the catheter main body 110. Therefore, when the surgeon operates the needle member 170, the needle member 170 can prevent the tip portion 171 of the needle member 170 from moving in a direction perpendicular to the longitudinal direction of the catheter main body 110. Therefore, even if the tip 171 of the needle member 170 is inserted deeper than expected, the tip 171 of the needle member 170 is less likely to reach the catheter body 110 or the cover member 160, and the tip 171 of the needle member 170 can be prevented from damaging the catheter body 110 or the cover member 160. The material of the hub body 120 is harder than the material of the catheter body 110. Therefore, it is preferable that the tip 171 of the needle member 170 faces the direction of the hub body 120. By configuring in this way, when the surgeon operates the needle member 170, it is possible to more reliably prevent the tip 171 of the needle member 170 from damaging the catheter body 110. Therefore, it is more preferable that the base 173 of the needle member 170 is located at a different position from the drug section 131 in the longitudinal direction of the catheter body 110, and the tip 171 of the needle member 170 faces the hub body 120.

[0067] The introducer sheath 100 also has a cover member 160 configured to be positioned from a position on the proximal side of the tip of the support member 130 to a position on the distal side of the tip of the support member 130 in the longitudinal direction of the catheter main body 110. The cover member 160 covers at least a part of the recess 112, and the tip of the cover member 160 is positioned so as to be positioned on the proximal side of the tip of the recess 112. In this manner, the cover member 160 covers the recess 112 from a position on the proximal side of the tip of the support member 130. Therefore, when the operator releases the drug solution, the cover member 160 can prevent the drug solution from coming into contact with the operator's hand. Also, the cover member 160 is positioned on the proximal side of the tip of the recess 112. Therefore, the operator can visually confirm the position of the tip of the recess 112 from which the drug solution is released, and therefore, when the introducer sheath 100 is placed in a biological lumen, the tip of the recess 112 from which the drug solution is released can be easily positioned so as to be located in biological tissue. The cover member 160 is located from a position on the proximal side of the tip of the support member 130 to a position on the distal side of the tip of the support member 130, and covers the recess 112 of the catheter body 110, which has a thin wall, thereby improving the rigidity of the introducer sheath 100. Therefore, the cover member 160 suppresses kinking of the catheter body 110 at the tip of the support member 130 when the operator places the introducer sheath 100 in the biological lumen. The cover member 160 may also be provided with a scale marking. This allows the operator to grasp the tip position of the recess 112 even when the introducer sheath 100 is placed in the biological lumen, and therefore the operator can easily grasp the tip position of the recess 112 even when the catheter body 110 moves during a predetermined procedure.

[0068] (Modification 1 of the first embodiment) FIG. 7(A) shows an introducer sheath 100a according to a modification of the first embodiment, and corresponds to the left side of the center line in FIG. 3. In the first embodiment, the space 180 is located on the base end side of the catheter main body 110 with respect to the drug section 131 and the partition wall 132, and the tip 171 of the needle member 170 is inserted into the support member 130 so as to face the tip side of the catheter main body 110. However, the tip of the needle member may be configured to face the base end side of the catheter main body as in this modification. In this modification, the configurations of the drug section 131a, partition wall 132a, space 180a, and needle member 170a provided in the support member 130a are different from those of the first embodiment, and the other configurations are the same as those of the first embodiment. Therefore, a description of the configurations common to the first embodiment will be omitted.

[0069] The space 180a is configured to be located on the distal end side of the catheter body 110 with respect to the medicinal agent section 131a and the partition section 132a. Other configurations of the medicinal agent section 131a and the partition section 132a are similar to those in the first embodiment, and therefore description thereof will be omitted.

[0070] The needle member 170a includes a tip portion 171, a main body portion 172, and a base portion 173, similar to the needle member 170 of the first embodiment. Unlike the first embodiment, the needle member 170a is configured so that the tip portion 171 faces the base end side of the catheter main body 110 when inserted into the support member 130. The other configurations of the needle member 170a are similar to those of the first embodiment, and therefore will not be described.

[0071] Moreover, the treatment method using the introducer sheath 100a according to this modification is the same as that in the first embodiment, and therefore will not be described.

[0072] As described above, in this first modification, the space 180a is located on the tip side of the catheter main body 110 relative to the drug section 131a and the partition section 132a, and the needle member 170a is configured to be inserted into the support member 130 so that the tip portion 171 of the needle member 170a faces the base end side of the catheter main body 110. Even in this configuration, a medicinal liquid can be administered to the wound site P via the recess 112 of the catheter main body 110 by a simple operation, as in the first embodiment, and the time required for hemostasis at the wound site P of the patient can be shortened, thereby reducing the burden on the patient and the surgeon.

[0073] (Modification 2 of the first embodiment) FIG. 7(B) shows the introducer sheath 100b of the second modification of the first embodiment, which is a view corresponding to the left side of the center line in FIG. 3. The needle member 170 of the first embodiment and the needle member 170a of the first modification have been described as being inserted into the support member 130 or the support member 130a with the main body 172 and the base 173 of the needle member 170, 170a exposed to the outside of the support member 130 or the support member 130a. However, the support member may be configured to have a convex portion that covers at least the main body portion of the needle member. The second modification is different from the introducer sheath 100a of the first modification in that the support member 130b has a convex portion 134, and the other configurations are the same as those of the first modification. Therefore, a description of the configurations common to the second modification and the first modification will be omitted.

[0074] The protrusion 134 covers the main body 172 and base 173 of the needle member 170a located outside the support member 130b. The protrusion 134 is provided on the outer surface of the support member 130b while covering the main body 172 and base 173 of the needle member 170a. The protrusion 134 is configured to press the main body 172 and base 173 of the needle member 170a when the surgeon presses the protrusion 134, and move the tip of the needle member 170a toward the partition wall 132a. The material of the protrusion 134 is not particularly limited. For example, the material of the protrusion 134 may be a resin material such as polyamide resin or polycarbonate resin, or a metal material, or may be the same material as the support member 130b, such as silicone rubber. It is preferable that the material convex portion 134 is made of a material having a higher hardness than the material constituting support member 130b so that the surgeon can easily press convex portion 134 and thereby press needle member 170a.

[0075] The treatment method using the introducer sheath 100b according to the second modification is different from the first embodiment in the operation of destroying the partition 132a when administering the medicinal liquid of the medicinal portion 131a to the wound site P. In the first embodiment, the surgeon performs an operation of pushing in the base portion 173 of the needle member 170 located outside the support member 130 with the recessed portion 112 of the catheter main body 110 inserted into the wound site P. On the other hand, in the second modification, the surgeon performs an operation of pressing the convex portion 134 with the fingers or the like with the recessed portion 112 of the catheter main body 110 inserted into the wound site P. As a result, the pressure of the fingers or the like is transmitted to the entire surface of the convex portion 134, the convex portion 134 moves radially inward of the support member 130b, the main body portion 172 covered by the convex portion 134 moves so as to be pushed into the tip side of the needle member 170a, and the tip portion 171 of the needle member 170a damages and destroys the partition portion 132a. The rest is the same as in the first modification of the first embodiment, and therefore a description thereof will be omitted.

[0076] As described above, in introducer sheath 100b according to modification 2, support member 130b is configured to include protrusion 134 that covers main body 172 of needle member 170a located outside support member 130b. Therefore, the surgeon can easily grasp the base end position of needle member 170a from the position of protrusion 134, and can push the tip end of needle member 170a in the direction of bulkhead 132a by pressing protrusion 134.

[0077] (Third Modification of the First Embodiment) Fig. 8 shows a medical elongated body set Sc according to a modification of the first embodiment, and is a view corresponding to the left side of the center line in Fig. 3. In the first embodiment, modification 1, and modification 2, the needle members 170, 170a are described as being inserted into the support members 130, 130a, and 130b, but this is not limited thereto. Before use, the medical elongated body may not have the needle member 170c inserted into the support member 130c, and the surgeon may insert the needle member 170c into the support member 130c when the medical elongated body is used.

[0078] The medical elongated body set Sc of the present modified example 3 is composed of an introducer sheath 100c and a needle member 170c. In the medical elongated body set Sc, the introducer sheath 100c and the needle member 170c are separated in an unused state. That is, the introducer sheath 100c is in a state where the needle member 170 is not inserted into the support member 130 in the introducer sheath 100 of the first embodiment. In addition, the introducer sheath 100c according to the present modified example differs from the first embodiment in the configurations of the drug section, partition section, space section, and needle member provided in the support member 130c in addition to the needle member, but the other configurations are similar. Therefore, a description of the configurations common to the modified example 3 and the first embodiment will be omitted.

[0079] In the third modification, the needle member 170c is not inserted in advance into the support member 130c. The needle member 170c is configured as a separate member from the introducer sheath 100c. The support member 130c is configured to include a marker portion 135 that serves as a guide when inserting the needle member 170c in the circumferential direction of the catheter main body 110. In the third modification, as shown in FIG. 8, when the operator presses the base portion 173 of the needle member 170c in a direction perpendicular to the longitudinal direction of the catheter main body 110, the tip portion of the needle member 170c moves at an inclination with respect to the direction perpendicular to the longitudinal direction of the catheter main body 110. Therefore, the marker portion 135 is provided at a position different from the drug portions 131 and 131a in the longitudinal direction of the catheter main body 110. In this embodiment, the marker portion 135 is configured by providing a recess on the outer surface of the support member 130c. However, as long as a user such as an operator can visually recognize the insertion position of needle member 170c, the specific configuration of the marker portion is not limited to a depression.

[0080] The support member 130c has medicinal sections 131, 131a and partitions 132, 132a as shown in Fig. 8. The medicinal section 131 and the partition 132 are configured to be located on the distal end side of the catheter main body 110 with respect to the space 180c. The medicinal section 131a and the partition 132a are configured to be located on the proximal end side of the catheter main body 110 with respect to the space 180c. In this modification, the medicinal section and the partition are provided at two locations on the support member as shown in Fig. 8. When the medicinal section and the partition are provided at only one location on the support member, it is preferable to provide them on the proximal end side of the catheter main body because the medicinal solution in the medicinal section 131 is likely to flow out of the distal end side of the recess 112 due to gravity when the recess 112 of the catheter main body 110 is inserted into the wound site P.

[0081] 8, needle member 170c includes a first needle member 170c1, a second needle member 170c2, and a pressing portion 174. Needle member 170c is configured to destroy partition portion 132 with first needle member 170c1, and to destroy partition portion 132a with second needle member 170c2.

[0082] The first needle member 170c1 has a sharp tip portion capable of destroying the partition wall portion 132, and the second needle member 170c2 has a sharp tip portion capable of destroying the partition wall portion 132a. The first needle member 170c1 and the second needle member 170c2 are configured so that their base ends are attached to the pressing portion 174. In addition, the first needle member 170c1 and the second needle member 170c2 are attached to the pressing portion 174 at a position where the first needle member 170c1 and the second needle member 170c2 intersect so that the partition walls 132, 132a can be destroyed as shown in FIG.

[0083] The pressing portion 174 is not particularly limited as long as it has a shape that is easy for a user such as a surgeon to press in this modified example. For example, the pressing portion 174 can be configured with a cylindrical member as shown in Fig. 8. However, the pressing portion 174 may be configured with a member other than a cylindrical shape (for example, a prism-shaped member, etc.). Furthermore, the pressing surface of the pressing portion 174 can be configured with a flat surface, but it may also be a curved surface other than a flat surface.

[0084] In the treatment method using the medical elongated body set Sc according to the third modification, the operation of destroying the partition when administering the medicinal liquid of the medicinal section to the wound site P is different from that in the treatment method using the introducer sheath 100 according to the first embodiment. In the third modification, the surgeon inserts the needle member 170c into the support member 130c with the recess 112 of the catheter main body 110 inserted into the wound site P. Specifically, the surgeon inserts the first needle member 170c1 and the second needle member 170c2 into the support member 130c using the marker portion 135 of the support member 130c as a guide from a state in which the recess 112 of the catheter main body 110 is inserted into the wound site P and the needle member 170c is not inserted into the support member 130c (see the needle member 170c shown by the two-dot chain line in FIG. 8).

[0085] The surgeon inserts needle member 170c into support member 130c, destroying partition 132 with first needle member 170c1 and destroying partition 132a with second needle member 170c2. This allows the surgeon to administer the medicinal liquid of medicinal portion 131 and the medicinal liquid of medicinal portion 131a to wound site P through recess 112. Other explanations are omitted as they are the same as those in the first embodiment.

[0086] As described above, the medical elongated body set Sc according to the third modification includes the introducer sheath 100c and the needle member 170c having a sharp tip portion configured to be able to destroy the partitions 132, 132a. The support member 130c is configured to include a marker portion 135 that serves as a guide when inserting the needle member 170c in the circumferential direction of the catheter main body 110. Therefore, even if the needle member 170c is a separate member from the introducer sheath 100c, the partitions 132, 132a can be destroyed by inserting the needle member 170c using the marker portion 135 as a guide with the recess 112 of the catheter main body 110 inserted into the wound site P, and the medicinal liquid of the medicinal portion 131, 131a can be administered to the wound site P via the recess 112.

[0087] (Fourth Modification of the First Embodiment) FIG. 9 is a view showing a medical elongated body set Sd according to a fourth modification of the first embodiment, which is a view corresponding to the left side of the center line in FIG. 3. In the medical elongated body set Sd of the fourth modification, the introducer sheath 100d and the needle member 170d are separated in an unused state, as in the third modification. That is, the introducer sheath 100d is in a state in which the needle member 170 is not inserted into the support member 130 in the introducer sheath 100 of the first embodiment. In addition, the medical elongated body set Sd is configured such that, in a state in which the needle member 170d is inserted into the medicinal portion 131d, the position of the base portion 173 of the needle member 170d is located at the same position as the medicinal portion 131d in the longitudinal direction of the catheter main body 110. That is, the position of the base portion 173 of the needle member 170d is configured to overlap with the medicinal portion 131d in the radial direction of the catheter main body.

[0088] The introducer sheath 100d has the same configuration as the introducer sheath 100c except for the medicinal portion and the partition portion.

[0089] In this modification, the drug section 131d is configured to be contained in the internal space of the support member 130d by the partition 132d. The partition 132d is configured to extend in the longitudinal direction of the catheter body 110. The space 180d is formed adjacent to the drug section 131d across the partition 132d in the radial direction of the catheter body 110. With this configuration, when the surgeon inserts the needle member 170d into the partition 132d, the drug solution in the drug section 131 can be made to flow out into the recess 112. In the modification 4, as shown in FIG. 9, since the needle member 170d is a straight rod member, the marker section 136 is provided at a position overlapping with the drug section 131d in the longitudinal direction of the catheter body 110. The other configurations of the marker section 136 are similar to those of the marker section 135 in the modification 3, and therefore will not be described.

[0090] In the fourth modification, the surgeon inserts the needle member 170d into the support member 130d at the same position in the longitudinal direction of the catheter main body 110 as the medicinal section 131d, and destroys the partition section 132d.

[0091] 9, the needle member 170d includes a tip portion 171d, a main body portion 172d, and a scale portion 175. The tip portion 171d of the needle member 170d has a sharp shape and is configured so as to be capable of destroying the partition portion 132d by damaging it. The main body portion 172d of the needle member 170d is located closer to the base end than the tip portion 171d, and can be grasped by a user such as a surgeon.

[0092] The scale portion 175 is provided on the main body portion 172d of the needle member 170d, and is configured so that the degree of insertion of the needle member 170d when the needle member 170d is inserted into the support member 130d can be visually confirmed. When the operator forms a hole in the partition portion 132d with the needle member 170d and causes the drug solution in the drug section 131d to flow into the space portion 180d, the operator needs to form a hole in the partition portion 132d by inserting the needle member 170d into the partition portion 132d and then removing the needle member 170d from the partition portion 132d. Therefore, in the case of the modification example 4 of FIG. 9, the operator needs to insert the needle member 170d into the partition portion 132d on the catheter main body 110 side, and then completely pull out the needle member 170d from the support member 130d, or at least pull out the needle member 170d to the vicinity of the drug section 131d, to cause the drug solution in the drug section 131 to flow out. The scale portion 175 can indicate the insertion limit when the needle member 170d is inserted so as to penetrate the partition wall portion 132d of the support member 130d. As a result, the scale portion 175 can prevent the surgeon from excessively inserting the needle member 170d and damaging the catheter main body 110, etc., when inserting the needle member 170d into the support member 130d. In addition, the scale portion 175 serves as a guide for the surgeon when the surgeon causes the drug solution in the drug section 131d to flow out when the surgeon pulls out the needle member 170d from the support member 130d. Therefore, the surgeon can administer the drug solution to the wound site P through the recess 112 without completely removing the needle member 170d from the support member 130d. For example, the scale portion 175 can be given at 1 mm intervals. However, the specific configuration of the scale is not limited to the above as long as it can suppress excessive insertion into the support member 130d.

[0093] In the treatment method using the medical elongated body set Sd according to the fourth modification, the operation of destroying the partition wall portion 132d with the needle member 170d when administering the medicinal liquid of the medicinal section to the wound site P is different from that of the first embodiment. When inserting the needle member 170d, the surgeon inserts the needle member 170d using the marker portion 136 of the support member 130d as a guide with the recessed portion 112 of the catheter main body 110 inserted into the wound site P. Specifically, with the recessed portion 112 of the catheter main body 110 inserted into the wound site P, the surgeon inserts the needle member 170d so as to penetrate the partition wall portion 132d using the marker portion 136 of the support member 130d located at the same position as the medicinal section 131d in the longitudinal direction of the catheter main body 110 as a guide. When inserting the needle member 170d, the surgeon can prevent the needle member 170d from being inserted too far into the catheter main body 110 by performing the insertion operation while checking the scale portion 175 of the needle member 170d.

[0094] When the needle member 170d is inserted into the puncture site with the recess 112 of the catheter body 110 inserted, the partition portion 132d is destroyed and the medicinal liquid of the medicinal portion 131 can be administered to the wound site P through the recess 112.

[0095] As described above, in the fourth modification, the needle member 170d is a separate member from the introducer sheath 100d, and the main body portion 172d of the needle member 170d is provided with the scale portion 175. With this configuration, it is possible to prevent the needle member 170d from being inserted too far into the catheter main body 110 when inserting the needle member 170d into the bulkhead portion 132d.

[0096] Similarly to the third modification, the medical elongated body set Sd of the fourth modification includes an introducer sheath 100d and a needle member 170d having a sharp tip portion configured to be able to destroy the partition portion 132d, and the support member 130d is configured to include a marker portion 136 that serves as a guide when inserting the needle member 170d in the circumferential direction of the catheter main body 110. Therefore, even if the needle member 170d is a separate member from the introducer sheath 100d, with the recess 112 of the catheter main body 110 inserted into the wound site P, the needle member 170d can be inserted using the marker portion 136 as a guide to destroy the partition portion 132d, and the medicinal solution of the medicinal portion 131d can be administered to the wound site P via the recess 112.

[0097] (Fifth Modification of the First Embodiment) Fig. 10(A) shows a sheath for introducer 100e according to a fifth modification of the first embodiment, and is a view corresponding to the left side of the center line in Fig. 3. Fig. 10(B) shows the sheath for introducer 100e according to the fifth modification in a transparent state, with the medicinal portions 131, 131a, the needle member 170e, etc., viewed from the radially outward direction of the catheter main body 110.

[0098] To briefly explain the fifth modification with reference to Figs. 10(A) and 10(B), the fifth modification is configured such that the partitions 132, 132a are broken and the drug solution in the drug sections 131, 131a is released into the recesses 112 by rotating the needle member 170e relative to the support member 130e. Note that the configuration of the needle member 170e in the fifth modification is different from that of the needle member 170c in the third modification. The fifth modification is different from the third modification in that the needle member 170e is not configured separately from the introducer sheath and the support member 130e does not have the marker section 135 provided for the support member 130c in Fig. 8. The other configurations of the fifth modification are the same as those of the third modification, and therefore a description of the common configurations will be omitted.

[0099] 10(A) and 10(B), needle member 170e according to this modification includes a first tip portion 171e1, a second tip portion 171e2, and a main body portion 172e. Main body portion 172e of needle member 170e includes a rotating plate 172e1, a rotating shaft 172e2, and a grip portion 172e3.

[0100] The rotating plate 172e1 is configured as a plate-like member having a rectangular shape when viewed in a plan view as shown in FIG. 10(B). Specifically, the rotating plate 172e1 has a rectangular shape when viewed in a plan view as shown in FIG. 10(B). The first tip 171e1 is configured to be sharp so as to be able to break the partition wall portion 132, and is provided on one surface of the rotating plate 172e1. The first tip 171e1 is provided on one surface of the rotating plate 172e1, near an end of the rotating plate 172e1 in the width direction of the rotating plate 172e1 (the up-down direction in FIG. 10(B)). The second tip 171e2 is configured to be sharp so as to be able to break the partition wall portion 132a, and is provided on the surface of the rotating plate 172e1 opposite to the surface on which the first tip 171e1 is provided. The second tip portion 171e2 is provided on the rotating plate 172e1 near an end portion located on the opposite side of the rotating plate 172e1 in the width direction of the rotating plate 172e1 from the position where the first tip portion 171e1 is provided. The first tip portion 171e1 and the second tip portion 171e2 are configured to be located in the space portion 180c.

[0101] The rotating shaft 172e2 is provided adjacent to the rotating plate 172e1 and is configured to be located outward of the rotating plate 172e1 in the radial direction of the catheter main body 110. When the operator rotates the rotating shaft 172e2, the rotating plate 172e1 rotates clockwise around the rotating shaft 172e2 as shown in FIG.

[0102] The grip portion 172e3 is provided adjacent to the rotating shaft 172e2 and is configured to be located outward of the rotating shaft 172e2 in the radial direction of the catheter main body 110. The grip portion 172e3 is configured to be grippable by the fingers of a user such as an operator. As shown in Fig. 10(A), the grip portion 172e3 is configured to be located outside the support member 130e.

[0103] The partition wall of the support member 130e is provided in two places, partition wall 132 and partition wall 132a, as in the third modification of Fig. 8. The partition wall 132 and partition wall 132a are configured to come into contact with the first tip portion 171e1 and the second tip portion 171e2 and be destroyed when the operator rotates the rotating plate 172e1. As shown in Fig. 10(B), the partition wall 132 and partition wall 132a do not come into contact with the first tip portion 170e1 and the second tip portion 170e2 when the end of the rotating plate 172e1 is at the farthest position from the partition wall portions 132 and 132a. On the other hand, when the surgeon rotates the rotating plate, the partition portion 132 and the partition portion 132a come into contact with the first tip portion 171e1 and the second tip portion 171e2 and are destroyed by moving the position near the end of the rotating plate 172e1 in the rotational direction shown in Figure 10 (B).

[0104] A treatment method using the introducer sheath 100e according to the fifth modification is different from the first embodiment in the operation of destroying the partitions 132, 132a with the needle member 170e when the surgeon administers the medicinal liquid of the medicinal sections 131, 131a to the wound site P. In the treatment method using the introducer sheath 100e according to the fifth modification, the surgeon holds the gripping section 172e3 with the recess 112 of the catheter main body 110 inserted into the wound site P, and rotates the rotating plate 172e1 around the rotating shaft 172e2. In detail, as shown in Figures 10(A) and 10(B), the surgeon grasps the grasping portion 172e3 before the needle member 170e destroys the partition portions 132, 132a (a state in which the first tip portion 171e1 and the second tip portion 171e2 of the rotating plate 172e1 are not in contact with the partition portions 132, 132a) and rotates the rotating plate 172e1 around the rotating shaft 172e2.

[0105] As a result, the first tip 171e1 comes into contact with the partition 132, damaging and destroying the partition 132. The second tip 171e2 comes into contact with the partition 132a, damaging and destroying the partition 132a. At this time, after the first tip 171e1 and the second tip 171e2 come into contact with the partitions 132 and 132a, the operator returns the rotating plate 172e1 to its original position before the first tip 171e1 and the second tip 171e2 come into contact with the partitions 132 and 132a, thereby forming holes in the partitions 132 and 132a. As a result, the medicinal liquid of the medicinal portion 131 and 131a flows out from the holes (damaged parts) of the partitions 132 and 132a into the space 180c and is administered to the wound site P through the recess 112. Other than that, the method of using the fifth modified example is similar to that of the first embodiment, and therefore a description thereof will be omitted.

[0106] As described above, the introducer sheath 100e according to the fifth modification is configured to move the positions of the first tip 171e1 and the second tip 171e2 of the needle member 170e by operating the gripping portion 172e3 of the needle member 170e and rotating the rotating plate 172e1, thereby destroying the partitions 132 and 132a. The needle member 170e has the sharp first tip 171e1 and the sharp second tip 171e2 configured to be able to destroy the partitions 132 and 132a, and the main body 172e extending from the first tip 171e1 and the sharp second tip 171e2 toward the outside of the support member 130e. The gripping portion 172e3, which is a part of the main body 172e, is configured to be located outside the support member 130c. With this configuration, the surgeon can operate the gripping portion 172e3 located on the outside of the support member 130c with the first tip portion 171e1 and the second tip portion 171e2 while the recessed portion 112 of the catheter main body 110 is inserted into the wound site P, and destroy the partitions 132, 132a. This allows the surgeon to administer the medicinal liquid of the medicinal portions 131, 131a to the wound site P. Note that, although it has been described that two medicinal portions and partitions are provided in this modified example, the number of medicinal portions and partitions is not limited to two as long as the partitions can be destroyed by rotating the needle member to release the medicinal liquid from the medicinal portion.

[0107] Second embodiment Fig. 11 is a view of a sheath for introducer 100f according to a second embodiment, which is a view corresponding to the left side of the center line in Fig. 3. To summarize the second embodiment with reference to Fig. 11, in the sheath for introducer 100f, a cover member 160f is fixed to a hub body 120. The cover member 160f has a hole portion 161, and a main body portion 172f of a needle member 170f is fixed to the cover member 160f. Note that the support member, cover member, and needle member in the second embodiment are different from those in the first embodiment. In addition, the other parts of the second embodiment are similar to those of the first embodiment, and therefore a description of the common configuration will be omitted.

[0108] The drug section 131f is made of the same material as in the first embodiment, but is accommodated at a different position in the support member 130f. The drug section 131f is configured to be accommodated in the internal space of the support member 130f by the partition wall 132f. The drug section 131f is configured to be adjacent to the needle member 170f across the partition wall 132f in the radial direction of the catheter main body 110 (support member 130f). In this embodiment, the drug section 131f is configured to be disposed outside the needle member 170f in the radial direction of the catheter main body 110 (support member 130f).

[0109] The partition section 132f is located closer to the catheter main body than the medicinal agent section 131f in the internal space of the support member 130f, and is configured to extend in the longitudinal direction of the catheter main body 110. As shown in Fig. 11, the space section 180f is formed adjacent to the medicinal agent section 131f in the radial direction of the catheter main body 110, sandwiching the partition section 132f therebetween. Note that the support member 130f can be given a color or the like different from the surrounding area only to the portion containing the medicinal agent section 131f so that the surgeon can easily recognize the position of the medicinal agent section 131f, thereby preventing another portion from being pressed by mistake during the procedure.

[0110] The cover member 160f is configured to be located from a position on the proximal side of the tip of the support member 130f to a position on the distal side of the tip of the support member 130f in the longitudinal direction of the catheter main body 110, similar to the cover member 160. The cover member 160f is configured to cover a part of the recess 112, and the tip of the cover member 160f is disposed to be located on the proximal side of the tip of the recess 112.

[0111] In the second embodiment, as shown in Fig. 11, the base end of the cover member 160f is fixed to the hub body 120. The cover member 160f is made of a substantially cylindrical material as in the first embodiment, and includes a needle member 170f. The needle member 170f is fixed to the cover member 160f. As in the first embodiment, the cover member 160f is made of a metal material or a fluorine-based resin that is harder than the material of the catheter body 110 so that the outer diameter of the cover member 160f can be maintained when the catheter body 110 is inserted into the biological tissue, and the cover member 160f can be smoothly inserted into the biological tissue.

[0112] In the second embodiment, as shown in FIG. 11, the cover member 160f is provided with a hole 161 at a position connecting the recess 112 and the space 180f in the circumferential direction of the catheter main body 110. As a result, when the operator destroys the partition 132f with the needle member 170f, the medicinal liquid in the medicinal portion 131f is discharged from the tip of the recess 112 through the space 180f, the hole 161 in the cover member 160f, and the recess 112. Therefore, when the operator destroys the partition 132f with the recess 112 of the catheter main body 110 inserted into the wound site P, the medicinal liquid in the medicinal portion 131f is administered to the wound site P through the recess 112. As shown in FIG. 11, it is preferable to provide a plurality of holes 161 in the cover member 160f so that the medicinal liquid in the medicinal portion 131f can efficiently flow out to the recess 112. The shape of the hole 161 may be circular or another shape. The specific number, shape, etc. of the holes 161 are not limited to the shape in FIG. 11 as long as the medicinal liquid in the medicinal portion 131f can be discharged to the wound site P through the recess 112.

[0113] Needle member 170f includes a sharp tip portion 171f capable of breaking partition portion 132f, and a main body portion 172f located on the base end side of tip portion 171f. As shown in FIG. 11, main body portion 172f of needle member 170f is fixed to cover member 160f such that tip portion 171f of needle member 170f faces the direction of support member 130f.

[0114] In the treatment method using the introducer sheath 100f according to the second embodiment, when the surgeon administers the medicinal liquid of the medicinal portion 131f to the wound site P, the operation of destroying the partition wall portion 132f by the needle member 170f is different from that of the first embodiment. In the treatment method using the introducer sheath 100f according to the second embodiment, the surgeon presses the support member 130f toward the catheter main body 110 in a state in which the recessed portion 112 of the catheter main body 110 is inserted into the wound site P. At this time, the surgeon presses and recesses the outer surface of the support member 130f so that the partition wall portion 132f comes into contact with the needle member 170f located in the cover member 160f. As a result, the needle member 170f approaches the partition wall portion 132f, and the tip portion 171f of the needle member 170f presses and destroys the partition wall portion 132f.

[0115] As a result, the medicinal liquid in medicinal section 131f is released from the broken portion of partition 132f through space 180f and hole 161 into recess 112 and administered to wound site P. Since the rest is the same as in the first embodiment, a description thereof will be omitted.

[0116] As described above, in the second embodiment, the base end of the cover member 160f is fixed to the hub body 120, and the cover member 160f is configured to have the hole 161 at a position connecting the recess 112 and the space 180f in the circumferential direction of the catheter body 110. In this manner, the base end of the cover member 160f is fixed to the hub body 120. Therefore, the cover member 160f of the second embodiment can prevent the base end of the cover member 160f from moving (displacing) when the operator places the cover member 160f in the living tissue. Therefore, the operator can smoothly insert the introducer sheath 100f into the blood vessel, improving the operator's operability. In addition, the cover member 160f has the hole 161. Therefore, with the recess 112 of the catheter body 110 inserted into the wound site P, the operator can administer the medicinal liquid of the medicinal section 131f to the wound site P through the hole 161 and the recess 112. Furthermore, when the constituent material of the hub body 120 is harder than the constituent material of the support member 130f, the base end of the cover member 160f is fixed to the hub body 120, which is harder than the support member 130f. Therefore, when the surgeon inserts the introducer sheath 100f into a blood vessel, the surgeon can insert the cover member 160f into the blood vessel more smoothly, further improving the operability of the surgeon.

[0117] Furthermore, the main body portion 172f of the needle member 170f is configured to be fixed to the cover member 160f. With this configuration, the surgeon can destroy the partition portion 132f with the tip portion 171f of the needle member 170f fixed to the cover member 160f, with the recess 112 of the catheter main body 110 inserted into the wound site P, and administer the medicinal liquid of the medicinal portion 131f to the wound site P. Therefore, the surgeon can destroy the partition portion 132f with the needle member 170f and administer the medicinal liquid of the medicinal portion 131f to the wound site P with a simple operation of pressing the outer surface of the support member 130f.

[0118] (Modification of the second embodiment) FIG. 12 is an oblique view showing an introducer sheath 100g relating to a modified example of the second embodiment, and FIG. 13 is a cross-sectional view perpendicular to the longitudinal direction of the catheter main body 110 of FIG. 12, showing drug sections 131g1, 131g2, partition sections 132g1, 132g2, needle member 170g, and cover member 160f.

[0119] The modified example of the second embodiment will be generally described with reference to Figures 12 and 13. The first tip 171g1 of the needle member 170g faces the partition wall 132g1 in the circumferential direction of the support member 130g, and the second tip 171g2 faces the partition wall 132g2 in the circumferential direction of the support member 130g. Note that this modified example differs from the second embodiment in the drug section, partition wall, and needle member. Other configurations of this modified example are similar to those of the second embodiment, and therefore will not be described.

[0120] Support member 130g has drug portion 131g1 and drug portion 131g2 at different positions in the circumferential direction of support member 130g. Drug portions 131g1 and 131g2 are contained in the internal space of support member 130g by partition portions 132g1 and 132g2, respectively.

[0121] 13, space portion 180g is adjacent to drug portion 131g1 across partition wall 132g1 in the circumferential direction of support member 130g. Space portion 180g is adjacent to drug portion 131g2 across partition wall 132g2 in the circumferential direction of support member 130g. Space portion 180g is configured to be formed between drug portion 131g1 and drug portion 131g2 in the circumferential direction of support member 130g.

[0122] The cover member 160f has the same configuration as in the second embodiment, and therefore a detailed description thereof will be omitted.

[0123] The needle member 170g comprises a sharp first tip portion 171g1 configured to be capable of destroying the partition portion 132g1, a sharp second tip portion 171g2 configured to be capable of destroying the partition portion 132g2, and a main body portion 172g that connects the first tip portion 171g1 and the second tip portion 171g2 to the cover member 160f.

[0124] The first tip portion 171g1 is disposed so as to face the partition wall portion 132g1 in the circumferential direction of the support member 130g. The second tip portion 171g2 is disposed so as to face the partition wall portion 132g2 in the circumferential direction of the support member 130g.

[0125] The main body portion 172g is configured to be fixed to the cover member 160f. The main body portion 172g includes a first tip portion 171g1 on one side in the circumferential direction of the cover member 160f, and a second tip portion 171g2 on the other side.

[0126] In the treatment method using the introducer sheath 100g according to this modified example, the surgeon operates the needle member 170g to break the partitions 132g1, 132g2 when administering the medicinal liquid of the medicinal section to the wound site P. Specifically, with the recess 112 of the catheter main body 110 inserted into the wound site P, the surgeon rotates the support member 130g in the circumferential direction of the catheter main body 110 and the support member 130g.

[0127] When the operator rotates the support member 130g in the circumferential direction of the catheter body 110 and the support member 130g, counterclockwise rotation of the support member 130g in Fig. 13 causes the first tip portion 171g1 of the needle member 170g to come into contact with the partition portion 132g1, damaging and destroying the partition portion 132g1. At this time, the medicinal solution of the medicinal portion 131g1 is released from the destroyed portion of the partition portion 132g1 and administered to the wound site P through the hole portion 161 and the recess portion 112.

[0128] Furthermore, when the operator rotates the support member 130g in the circumferential direction of the catheter main body 110 and the support member 130g, if the operator rotates the support member 130g clockwise, the second tip portion 171g2 comes into contact with the partition portion 132g2, damaging and destroying the partition portion 132g2. At this time, similar to the medicinal portion 131g1, the medicinal solution in the medicinal portion 131g2 is released from the destroyed portion of the partition portion 132g2 and is administered to the wound site P through the hole portion 161 and the recessed portion 112. Other explanations are omitted because they are similar.

[0129] As described above, in this modified example, the main body 172g of the needle member 170g is fixed to the cover member 160f, as in the second embodiment. With this configuration, the surgeon can, with the recess 112 of the catheter main body 110 inserted into the wound site P, destroy the partitions 132g1, 132g2 with the first tip portion 171g1 and the second tip portion 171g2 of the needle member 170g, whose main body portion 172g is fixed to the cover member 160f, and administer the medicinal liquid of the medicinal portions 131g1, 131g2 to the wound site P through the hole portion 161 and the recess 112.

[0130] The present invention is not limited to the above-mentioned embodiment and modified examples, and various modifications are possible within the scope of the claims. Fig. 14 is a modified example of Modification 5 of the first embodiment, showing a modified recess of the catheter body. In the first embodiment, it has been described that the recess from which the drug solution flows out is provided at one location in the circumferential direction of the catheter body 110, but the present invention is not limited to this. For example, as shown in Fig. 14, the recess may be branched into multiple locations on the tip side of the catheter body 110.

[0131] In addition to providing a recess at one location in the circumferential direction of the catheter main body, the recess 112h may be configured to include a first portion 112h1 extending from the direction of the drug portion 131 toward the tip side of the catheter main body 110h, a second portion 112h2 extending from the tip of the first portion 112h1 in the circumferential direction of the catheter main body 110h, and third portions 112h3, 112h4, and 112h5 branching from the second portion 112h2 and extending toward the tip side of the catheter main body 110h along the longitudinal direction of the catheter main body 110h, as shown in Fig. 14. Note that the second portion 112h2 is preferably configured to be located at a position closer to the base end than the tip of the cover member 160. As a result, the catheter main body 110h is configured to suppress kinking starting from the second portion 110h2, since the second portion 110h2 extending in the circumferential direction of the catheter main body 110h is not exposed distally of the distal end of the cover member 160. For these reasons, from the viewpoint of insertability of the medical elongated body, it is preferable that the second portion 112h2 is not exposed from the cover member 160. Also, although three third portions are provided in Fig. 14, the specific number of third portions may be other than three.

[0132] By configuring in this manner, with the recess 112 of the catheter body 110 inserted into the wound site P, the surgeon can cause the medicinal liquid from the medicinal section 131 to flow out over a wide area in the circumferential direction of the catheter body 110, thereby administering the medicinal liquid to the wound site P.

[0133] Also, in the introducer sheaths of the first embodiment, modified example 1, modified example 2, modified example 3, modified example 4, and modified example 5, the cover member is fixed to the support member, and in the introducer sheaths of the second embodiment and modified examples, the cover member is fixed to the hub body. However, in the introducer sheaths, when the drug portion and the recess are communicable with each other when the partition wall is destroyed by the needle member, a cover member having a hole may be fixed to the hub body instead of fixing the cover member to the support member in the first embodiment, modified example 1, modified example 2, modified example 3, modified example 4, and modified example 5. Also, in the introducer sheaths, when the drug portion and the recess are communicable with each other when the partition wall is destroyed by the needle member, a cover member having a hole may be fixed to the support member in the same manner as in the first embodiment, instead of fixing the cover member having a hole to the hub body in the second embodiment and modified examples.

[0134] This application is based on Japanese Patent Application No. 2020-152098 filed on September 10, 2020, the disclosure of which is incorporated by reference in its entirety. [Explanation of symbols]

[0135] 100-100g introducer sheath (medical long body), 110, 110h Catheter body, 112 recesses, 120 Hub body, 130-130g Support member, 131 Pharmacy Department, 132 Bulkhead, 134 Convex part, 160 Cover member, 170 needle member, 171, 171d, 171f tip, 172, 172e, 172g main body, 180 Spatial Department, Sc, Sd Medical long body set.

Claims

1. A catheter body; a hub body secured to a proximal end of the catheter body; a support member coupled to the hub body and configured to cover a portion of the proximal end of the catheter body; The catheter body has a recess on an outer surface of the catheter body, The support member is disposed so as to partially cover the recess, The support member has a drug portion containing a drug solution and a partition portion located between the drug portion and the recess, The partition is configured to communicate the drug portion with the recess when the partition is broken by pressure or damage, A needle member having a sharp tip portion configured to be capable of destroying the partition portion; a space portion between the catheter body and the support member, the space portion being adjacent to the drug portion with the partition wall therebetween; The tip of the needle member is configured to be positioned in the space.

2. The needle member has the tip portion and a main body portion located on the base end side of the tip portion, The medical elongate body according to claim 1 , wherein a portion of the main body of the needle member is configured to be located outside the support member.

3. The needle member has a base portion located outside the support member, The medical elongate body according to claim 2 , wherein the base portion is located at a position different from the medicinal portion in the longitudinal direction of the catheter body.

4. The medical elongate body according to claim 2 , wherein the support member includes a protrusion that covers the main body portion located outside the support member.

5. a cover member configured to be positioned from a position on the proximal side of the tip of the support member to a position on the distal side of the tip of the support member in a longitudinal direction of the catheter body, The cover member covers at least a portion of the recess, The medical elongate body according to any one of claims 1 to 4, wherein a tip of the cover member is disposed so as to be located closer to the base end than a tip of the recess.

6. a cover member configured to be positioned from a position on the proximal side of the tip of the support member to a position on the distal side of the tip of the support member in a longitudinal direction of the catheter body, the cover member is disposed so as to cover at least a portion of the recess and such that a tip of the cover member is located on a proximal side relative to a tip of the recess, A base end of the cover member is fixed to the hub body, The medical elongate body according to claim 2 , wherein the cover member has a hole at a position connecting the recess and the space in a circumferential direction of the catheter body.

7. The medical elongate body according to claim 6 , wherein the main body portion of the needle member is fixed to the cover member.

8. A catheter body, a hub body secured to a proximal end of the catheter body; a support member coupled to the hub body and configured to cover a portion of the proximal end of the catheter body; The catheter body has a recess on an outer surface of the catheter body, The support member is disposed so as to partially cover the recess, The support member has a drug portion containing a drug solution and a partition portion located between the drug portion and the recess, the partition wall is configured to communicate with the drug portion and the recess portion when the partition wall is destroyed by pressure or damage; and a needle member having a sharp tip portion configured to be capable of destroying the partition wall, The support member is provided with a marker portion that serves as a guide when inserting the needle member in the circumferential direction of the catheter body.

Images